Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Items Tagged ‘Edward Loftus’

February 10th, 2017

FDA Approves Biosimilar to Humira

By Kanaaz Pereira kanaazpe

The FDA recently approved a biosimilar (trade name, Amjevita) to Humira (adalimumab). A biosimilar is a biological product that is highly similar to the originator drug, and has no clinical differences in terms of safety and effectiveness. Dr. Edward Loftus , M.D., talks about the potential of this drug to offer patients with chronic inflammatory diseases such as Crohn’s and ulcerative colitis an […]

View full entry

Tags: Amjevita, biosimilar, Crohn's disease, Edward Loftus, FDA, Humira, IBD, ulcerative colitis


May 6th, 2016

FDA Approves of Biosimilar to Infliximab

By Kanaaz Pereira kanaazpe

The FDA recently approved of a biosimilar (CT-P13) to infliximab, which is used for treating IBD patients, as well as patients suffering from rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. The new drug would be the first biosimilar monoclonal antibody approved in the United States. Dr. Edward Loftus, M.D., explains how biosimilars work, and discusses […]

View full entry

Tags: biosimilar, CT-P13, Edward Loftus, FDA, IBD, infliximab, rheumatoid arthritis


May 3rd, 2016

Vedolizumab Safe for Inflammatory Bowel Disease

By Kanaaz Pereira kanaazpe

Vedolizumab (proposed trade name Entyvio), was developed as a treatment for patients with moderate to severe ulcerative colitis (UC) or Crohn’s disease (CD), who have failed at least one conventional therapy, including tumor necrosis factor (TNF) antagonists. Dr. Edward Loftus, M.D., reviews a recent study published in the journal Gut, in which researchers reported on […]

View full entry

Tags: Crohn's disease, Edward Loftus, Entyvio, GUT, IBD, monoclonal antibody, ulcerative colitis, Vedolizumab


August 17th, 2015

Fecal Transplants for Ulcerative Colitis?

By Kanaaz Pereira kanaazpe

There is currently great interest in treating ulcerative colitis with fecal microbiota transplantation (FMT), which involves transplanting gut fecal bacteria from healthy people into patients with ulcerative colitis. Edward Loftus Jr., M.D., a gastroenterologist at Mayo Clinic, talks about two newly published studies in Gastroenterology; both studies examined the efficacy of fecal microbiota transplantation in ulcerative colitis, but arrived […]

View full entry

Tags: Edward Loftus, fecal transplant, Gastroenterology, IBD, ulcerative colitis


April 8th, 2015

New Treatment for Ulcerative Colitis

By Margaret Shepard, Communications Specialist Margaret_Marie

Edward Loftus Jr., M. D., discusses the recent Food and Drug Administration approval of a new treatment for ulcerative colitis. Dr. Loftus explains the process Uceris, a budesonide foam, went through to receive FDA approval. The phase three trials found higher remission rates, improvement in disease activity, and rectal bleeding. The new drug will be […]

View full entry

Tags: Edward Loftus, FDA, ulcerative colitis


February 27th, 2015

Elderly On-Set IBD Patients and Corticosteroids

By Margaret Shepard, Communications Specialist Margaret_Marie

Edward Loftus Jr., M. D., discusses a recently published article in The American Journal of Gastroenterology that looks at older, on-set inflammatory bowel disease patients with evidence of serious infections. The study concludes that elderly patients with IBD that take corticosteroids are two to three times more likely to develop an infection that is serious […]

View full entry

Tags: American Journal of Gastroenterology, corticosteroid, Edward Loftus, IBD


February 6th, 2015

Management of Refractory IBD

By Margaret Shepard, Communications Specialist Margaret_Marie

A majority of patients with inflammatory bowel disease (IBD) fail to respond, have an inadequate response or lose response to standard medical therapies. Although some patients may be truly refractory to medical treatment, in others, symptoms may be unrelated to the underlying IBD, according to Edward V. Loftus Jr. M.D., director of the IBD clinic […]

View full entry

Tags: Digestive Diseases Update, Edward Loftus, IBD, refractory IBD


January 16th, 2015

IBD and Pneumonia

By Margaret Shepard, Communications Specialist Margaret_Marie

Edward Loftus Jr., M.D., discusses a study published in American Journal of Gastroenterology that found patients with inflammatory bowel disease were at an increased risk of pneumonia. In addition, Dr. Loftus also discusses the patient implications brought about by the study findings. For more information about IBD, visit mayoclinic.org/ibd. Edward Loftus Jr., M.D., is a gastroenterologist […]

View full entry

Tags: American Journal of Gastroenterology, Edward Loftus, IBD, pneumonia


December 24th, 2014

Therapeutic Drug Monitoring of Anti-TNF Therapy

By Margaret Shepard, Communications Specialist Margaret_Marie

Therapeutic drug monitoring is now extending to newer biologics, including TNF inhibitors such as infliximab, a chimeric monoclonal antibody, and adalimumab, a fully human monoclonal antibody. Although these drugs have improved outcomes for some refractory patients, they have been unsatisfactory for others. Edward V. Loftus Jr., M.D., comments on the effectiveness of therapeutic drug monitoring […]

View full entry

Tags: Anti-TNF agents, drug therapy, Edward Loftus, IBD, therapeutic drug monitoring


December 18th, 2014

Vedolizumab Is Better for Ulcerative Colitis Than Crohn’s Disease

By Margaret Shepard, Communications Specialist Margaret_Marie

In December 2013, two Food and Drug Administration (FDA) advisory committees voted in favor of recommending vedolizumab for treatment of both types of inflammatory bowel disease. A theoretical concern about vedolizumab is the risk of progressive multifocal leukoencephalopathy (PML), a potentially fatal brain infection associated with vedolizumab’s parent molecule, natalizumab (Tysabri), which is approved for […]

View full entry

Tags: clinical trials, Crohn's disease, Edward Loftus, IBD, ulcerative colitis, Vedolizumab


Contact Us · Privacy Policy